Stock Events

Stock Events

ProQR Therapeutics N.V 

$1.6400
45
+$0.01+0.61% 09:57 Today

Statistics

Day High
1.645
Day Low
1.635
52W High
3.1
52W Low
1.33
Volume
46,576
Avg. Volume
-
Mkt Cap
230.02M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.15
-0.13
-0.11
-0.09
Expected EPS
-0.11453125684
Actual EPS
N/A

Financials

-266.16%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
18.25MRevenue
-48.57MNet Income

Analyst Ratings

$7.00Average Price Target
The highest estimate is 10.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PRQR. It's not an investment recommendation.
Tesla
11
TSLA
NVIDIA
11
NVDA
Amazon
9
AMZN
Apple
8
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Ionis Pharmaceuticals
IONS
Mkt Cap7.4B
Ionis Pharmaceuticals, Inc. specializes in RNA-targeted drug discovery and development, similar to ProQR's focus on RNA therapies for genetic disorders.
Alnylam Pharmaceuticals
ALNY
Mkt Cap34.25B
Alnylam Pharmaceuticals, Inc. is a leader in RNAi therapeutics, directly competing in the RNA-based treatment space that ProQR operates within.
Sarepta Therapeutics
SRPT
Mkt Cap1.97B
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for rare diseases, closely aligning with ProQR's mission.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.66B
BioMarin Pharmaceutical Inc. develops and commercializes innovative biopharmaceuticals for rare diseases and medical conditions, a market that ProQR also targets.
PTC Therapeutics
PTCT
Mkt Cap5.23B
PTC Therapeutics, Inc. engages in the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders, competing in ProQR's therapeutic area.
Ultragenyx Pharmaceutical
RARE
Mkt Cap1.43B
Ultragenyx Pharmaceutical Inc. is focused on the development of novel products for rare and ultra-rare diseases, including genetic disorders, which is a direct competition to ProQR's focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap133.37B
Vertex Pharmaceuticals Incorporated is known for its work in treating cystic fibrosis, a genetic disorder, which may overlap with ProQR's target diseases.
CRISPR Therapeutics
CRSP
Mkt Cap5.24B
CRISPR Therapeutics AG specializes in gene editing, a next-generation approach to treating genetic disorders, potentially competing with ProQR's RNA-based therapies.
Editas Medicine
EDIT
Mkt Cap396.24M
Editas Medicine, Inc. is involved in developing gene editing technologies to treat genetically driven diseases, offering an alternative to ProQR's approach.
Intellia Therapeutics
NTLA
Mkt Cap1.65B
Intellia Therapeutics, Inc. is a leading gene editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, competing in the genetic disease space with ProQR.

About

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
Show more...
CEO
Daniel Anton de Boer
Employees
187
Country
Netherlands
ISIN
NL0010872495
WKN
000A12B97

Listings

MX
MX
PRQRN.MX
STU
DE
0PQ.STU
F
DE
0PQ.F
MU
DE
0PQ.MU

0 Comments

Share your thoughts

FAQ

What is ProQR Therapeutics N.V stock price today?▼
The current price of PRQR is $1.64 USD — it has increased by +0.61% in the past 24 hours. Watch ProQR Therapeutics N.V stock price performance more closely on the chart.
What is ProQR Therapeutics N.V stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange ProQR Therapeutics N.V stocks are traded under the ticker PRQR.
Is ProQR Therapeutics N.V stock price growing?▼
PRQR stock has fallen by -1.21% compared to the previous week, the month change is a -24.19% fall, over the last year ProQR Therapeutics N.V has showed a -27.56% decrease.
What is ProQR Therapeutics N.V market cap?▼
Today ProQR Therapeutics N.V has the market capitalization of 230.02M
When is the next ProQR Therapeutics N.V earnings date?▼
ProQR Therapeutics N.V is going to release the next earnings report on November 05, 2026.
What were ProQR Therapeutics N.V earnings last quarter?▼
PRQR earnings for the last quarter are -0.09 USD per share, whereas the estimation was -0.13 USD resulting in a +29.86% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is ProQR Therapeutics N.V revenue for the last year?▼
ProQR Therapeutics N.V revenue for the last year amounts to 18.25M USD.
What is ProQR Therapeutics N.V net income for the last year?▼
PRQR net income for the last year is -48.57M USD.
How many employees does ProQR Therapeutics N.V have?▼
As of October 02, 2026, the company has 187 employees.
In which sector is ProQR Therapeutics N.V located?▼
ProQR Therapeutics N.V operates in the Health & Wellness sector.
When did ProQR Therapeutics N.V complete a stock split?▼
ProQR Therapeutics N.V has not had any recent stock splits.
Where is ProQR Therapeutics N.V headquartered?▼
ProQR Therapeutics N.V is headquartered in Leiden, Netherlands.